Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 8/20 | 0.90 |
| ▸ | MEN1 | O00255 | 1/20 | 0.90 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.90 |
| ▸ | RARA | P10276 | 1/20 | 0.90 |
| ▸ | MAPT | P10636 | 1/20 | 0.90 |
| ▸ | MTOR | P42345 | 1/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.90 |
| ▸ | THRA | P10827 | 2/20 | 0.67 |
| ▸ | THRB | P10828 | 2/20 | 0.67 |
| ▸ | ATG4B | Q9Y4P1 | 7/20 | 0.66 |
| ▸ | PLA2G1B | P04054 | 6/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | RECQL | P46063 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8080374 | 1.00 | RARB (0.90) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL18979307 | 1.00 | RARB (0.90) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL1164529 | 1.00 | RARB (0.90) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL503506 | 1.00 | RARB (0.90) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL18979350 | 1.00 | RARB (0.90) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL82569 | 1.00 | RARB (0.90) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL503648 | 1.00 | RARB (0.90) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL270423 | 1.00 | RARB (0.90) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL970162 | 1.00 | RARB (0.90) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL980560 | 1.00 | RARB (0.90) | RARBMEN1ALDH1A1RARAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180219160-A1 | BENZOBIS(THIADIAZOLE) DERIVATIVE, INK COMPRISING THE SAME, AND ORGANIC ELECTRONIC DEVICE USING THE SAME | UBE INDUSTRIES, LTD. (JP) | 2018-08-02 | — | — | US | disclosed |
| EP-2343306-B1 | Glycolipid derivatives, process for production of the same, intermediates for synthesis thereof, and process for production of the intermediates | JAPAN PRESIDENT NAT CT NEUROLOGY & PSYCHIATRY (JP) | 2018-04-04 | — | — | EP | disclosed |
| EP-3181569-A1 | BENZOBIS(THIADIAZOLE) DERIVATIVE, INK CONTAINING SAME, AND ORGANIC ELECTRONIC DEVICE USING SAME | UBE Industries, Ltd. (JP) | 2017-06-21 | — | — | EP | disclosed |
| CN-106661057-A | Benzobis(thiadiazole) derivative, ink containing same, and organic electronic device using same | 宇部兴产株式会社 | 2017-05-10 | — | — | CN | disclosed |
| US-8034908-B2 | Glycolipids and synthetic method thereof as well as their synthetic intermediates, and synthetic method thereof | JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2011-10-11 | — | — | US | disclosed |
| EP-2343306-A1 | Glycolipid derivatives, process for production of the same, intermediates for synthesis thereof, and process for production of the intermediates | Japan as represented by President of National Center of Neurology and Psychiatry Ministry of Health (JP) | 2011-07-13 | — | — | EP | disclosed |
| CN-101165047-B | Glycolipid derivative and its manufacturing method, and its synthesizing intermediate and its manufacturing method | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2010-10-20 | — | — | CN | disclosed |
| US-20100210828-A1 | NEW GLYCOLIPIDS AND SYNTHETIC METHOD THEREOF AS WELL AS THEIR SYNTHETIC INTERMEDIATES, AND SYNTHETIC METHOD THEREOF | JAPAN AS REPRESENTED BY THE PRESIDENT OF NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2010-08-19 | — | — | US | disclosed |
| US-7732583-B2 | Glycolipids and synthetic method thereof as well as their synthetic intermediates, and synthetic intermediates, and synthetic method thereof | JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2010-06-08 | — | — | US | disclosed |
| CN-100537585-C | Glycolipid derivative, process for producing the same, intermediate for the synthesis thereof, and process for producing the same | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2009-09-09 | — | — | CN | disclosed |
| CN-101165047-A | Glycolipid derivative and its manufacturing method, and its synthesizing intermediate and its manufacturing method | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2008-04-23 | — | — | CN | disclosed |
| CN-1768072-A | Glycolipid derivative, process for producing the same, intermediate for the synthesis thereof, and process for producing the same | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2006-05-03 | — | — | CN | disclosed |
| US-20060074235-A1 | Glycolipids derivatives, process for production of the same, intermediates for synthesis thereof, and process for production of the intermediates | JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2006-04-06 | — | — | US | disclosed |
| EP-1619199-A1 | GLYCOLIPID DERIVATIVES, PROCESS FOR PRODUCTION OF THE SAME, INTERMEDIATES FOR SYNTHESIS THEREOF, AND PROCESS FOR PRODUCTION OF THE INTERMEDIATES | Daiichi Asubio Pharma Co., Ltd. (JP) | 2006-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180219160-A1 | BENZOBIS(THIADIAZOLE) DERIVATIVE, INK COMPRISING THE SAME, AND ORGANIC ELECTRONIC DEVICE USING THE SAME | IKZF3, HELZ, TEC | RARB 695/4885MEN1 3053/4885ALDH1A1 246/4885 |
| US-20100210828-A1 | NEW GLYCOLIPIDS AND SYNTHETIC METHOD THEREOF AS WELL AS THEIR SYNTHETIC INTERMEDIATES, AND SYNTHETIC METHOD THEREOF | SGMS1, UGCG, SGMS2 | RARB 1765/4885MEN1 1232/4885ALDH1A1 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.